Harbor Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Harbor Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	92,669 +12,584	+16%	+$238K	0.11%	255
2026 Q1	$1.74M	Buy	+80,085	New	+$1.55M	0.14%	221
2025 Q3	–	Sell	-1,325	Closed	-$23K	–	1469
2025 Q2	$23K	Buy	1,325 +869	+191%	+$37.1K	﹤0.01%	784
2025 Q1	$29K	Sell	456 -1,250	-73%	-$132K	﹤0.01%	763
2024 Q4	$207K	Buy	1,706 +427	+33%	+$52.3K	0.01%	655
2024 Q3	$160K	Buy	1,279 +6	+0.5%	+$829	0.01%	693
2024 Q2	$201K	Sell	1,273 -77	-6%	-$9.89K	0.02%	640
2024 Q1	$175K	Sell	1,350 -440	-25%	-$53.9K	0.02%	640
2023 Q4	$173K	Sell	1,790 -1,454	-45%	-$139K	0.03%	371
2023 Q3	$393K	Buy	3,244 +196	+6%	+$22.2K	0.08%	260
2023 Q2	$349K	Sell	3,048 -1,065	-26%	-$137K	0.07%	301
2023 Q1	$567K	Buy	4,113 +1,829	+80%	+$237K	0.16%	128
2022 Q4	$296K	Buy	+2,284	New	+$265K	0.29%	72

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Harbor Capital Advisors's SRPT Position: Q2 2026 in Review

Harbor Capital Advisors increased its Sarepta Therapeutics (SRPT) stake by 16% in Q2 2026, buying an estimated $238K and bringing the position to 92,669 shares worth $1.67M. The position accounts for 0.11% of the portfolio, ranked #255.

Harbor Capital Advisors first reported a position in SRPT in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.74M in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Harbor Capital Advisors held 92,669 shares of Sarepta Therapeutics worth $1.67M as of Q2 2026.
Harbor Capital Advisors bought 12,584 Sarepta Therapeutics shares in Q2 2026, an estimated $238K.
Sarepta Therapeutics made up 0.11% of Harbor Capital Advisors's portfolio in Q2 2026, its #255 holding.
Harbor Capital Advisors first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 13 quarters since.
Harbor Capital Advisors's Sarepta Therapeutics position peaked at $1.74M in Q1 2026.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.